Overcoming Cell Therapy Manufacturing Challenges

2

April

  • 5 PM London / 12 PM New York / 9 AM Los Angeles
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Learning Objectives of this webinar:

  • Understand the key challenges when it comes to scaling up cell manufacturing
  • Learn about innovative systems and technologies implemented by industry leaders like ImmuneBridge and National Resilience to enhance scalability and efficiency in cell manufacturing
  • Gain insights into how advancements in automation and platform development are shaping the next generation of safer and more effective cell therapies.
  • Gather insights in cell therapy characterisation and quality control when scaling up manufacturing.

 

Cell manufacturing faces challenges such as maintaining consistency, scalability, and cost-effectiveness. Variability in cell behaviour, strict quality control requirements, and complex regulatory approvals make large-scale production difficult. Additionally, ensuring sterility, optimizing automation, and managing high production costs remain key obstacles in advancing efficient and reliable cell manufacturing processes.

We’ve invited speakers from both ImmuneBridge and National Resilience to discuss about the systems they have in place to develop and characterize scalable cell therapies. Herein, our audience will learn about the various considerations when it comes to developing a scalable cell manufacturing platforms, qualifying them, and how it can help advanced scalable cell therapy solutions.

Register now to discover how cell therapy manufacturing has advanced to be prepared to deliver the next generation of safer and more effective cell therapies.

Speakers

Select a speaker to learn more

Back
Ruiyuan Zheng, PhD
Marketing Product Manager, ACROBiosystems

Ruiyuan Zheng is a Marketing Product Manager at ACROBiosystems, specialising in cell and gene therapy (CGT) products. With a PhD in chromatin and cell biology from the University of Cologne and postdoctoral research in organoid-based disease models at Heidelberg University, she brings deep expertise in iPSC technology and its applications in regenerative medicine. Now, she focuses on customer engagement and marketing analysis, leveraging her scientific background to drive innovation and strategy in the CGT field.

Next speaker
Back
Grace Eppolito
Scientist, ImmuneBridge

Grace Eppolito is a scientist at ImmuneBridge, an early-stage cell therapy company in San Francisco. With over seven years of experience in upstream process development, I have worked extensively with CHO cells for monoclonal antibody production, leveraged the AAV/BEV system for gene therapies, and, for the past two years, have been focused on process development in the cell therapy space. The common thread throughout my career has been my expertise in bioreactor-based process development, optimizing and scaling up systems to drive therapeutic advancements.

Next speaker
Back
Brandon Razooky, PhD
Senior Scientist & Technical Lead, Resilience,

Brandon Razooky holds a PhD in Biophysics from University of California, San Francisco, and pursued postdoctoral research at The Rockefeller University, blending genome engineering, synthetic biology, and virology techniques to understand host cell responses to viral infections. Over the last few years, he has been working at National Resilience, Inc., focusing on enhancing the manufacturability and release of both gene and cell therapies. Currently focusing on cell therapy, the group he is a part of aims to provide automated solutions to cell characterization and QC release.

Next speaker

Enquiry